Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 1.Assessing Risk in NMIBC: A Foundation for Therapy

EP: 2.From Papillary to CIS: Tailoring NMIBC Treatment

EP: 3.Defining and Managing BCG-Unresponsive NMIBC

EP: 4.NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 5.FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

EP: 6.An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

EP: 7.An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 8.Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

Now Viewing

EP: 9.Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 10.Topline Results From Recent NMIBC Trials

EP: 11.Overcoming Challenges in Accessing New Therapies for NMIBC

EP: 12.Navigating Access Barriers: Resources to Support New Treatment Access

EP: 13.Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).

• ABLE-32 Trial: This is a phase 3, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of nadofaragene firadenovec in patients with intermediate-risk NMIBC. The study aims to assess the treatment’s ability to reduce the recurrence and progression of bladder cancer in this patient population.
• ABLE-41 Trial: This is a real-world, observational trial that investigates the use of nadofaragene firadenovec outside the controlled environment of clinical trials. The study seeks to gather data on its effectiveness and safety in routine clinical practice, providing insights into its use across a broader, more diverse patient population.

Both trials contribute to expanding the understanding of nadofaragene firadenovec as a potential treatment option for NMIBC.